Compound BW759 (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine) was shown to be about 230 times more active than acyclovir (9-[2-hydroxyethoxymethyl]guanine) (ACV) 
elucidated.
At present, Aujeszky's disease is enzootic in the United States and many European countries but is absent from Japan, Canada, and Australia. In pigs, the causal herpesvirus exhibits multiple tissue affinities; in addition to clinical signs of nervous derangement, respiratory symptoms and abortion are commonly seen, and economic losses in affected herds are consequently serious (3, 4) . Both live and killed porcine vaccines are available and appear equally effective in that they control clinical disease but do not prevent infection by, or excretion of, field strains and the possible setting up of a carrier state. Equid herpesvirus type 1 (equine abortion virus [EHV-11), also a member of the herpes group, occurs worldwide and causes respiratory disease, fetal and foal mortality, and neurological disorders (8) . Immunity to EHV-1 infection is short lived (7) , and although both living and inactivated vaccines are available, these may fail to provide adequate protection. An effective antiviral compound for these two herpesvirus diseases would therefore be of considerable value. Acyclovir (9-[2-hydroxyethoxymethyl]guanine) (ACV) has proven activity against herpes simplex both in vitro and in vivo (5, 6) and is now available (Zovirax; Wellcome Foundation Ltd., London, United Kingdom) for the treatment of certain herpetic conditions in humans. Activity in vitro has also been demonstrated against varicella zoster virus, Epstein-Barr virus, and cytomegalovirus (10) . Recently, a report has been published describing the potent antiviral activity of a close analog of ACV, 9-[2-hydroxy -1-(hydroxymethyl) ethoxymethyl]guanine (BIOLF-62), against herpes simplex virus in vitro (11) .
This paper reports studies with ACV and the analog, hereafter referred to as BW759 ( Fig. 1) , in vitro and in two laboratory animal disease models, Aujeszky's disease virus (Suid herpesvirus type 1 [SHV-1]) infection in mice and EHV-1 infection in Syrian hamsters.
MATERIALS AND METHODS
In vitro studies. The 50%o inhibitory concentrations of ACV and BW759 were calculated by the method of plaque reduction described by Collins and Bauer (6) . Pig kidney (PK15) cell monolayers were infected with 100 to 200 PFU of virus in 0.1 ml of phosphatebuffered saline and allowed to adsorb for 1 h before removal and overlay with a mixture of equal parts of double-strength maintenance medium and 1% agarose incorporating ACV or BW759 in doubling dilutions. Monolayers were incubated in 5% C02-air at 37°C and fixed and stained 4 to 5 days later. The 50% inhibitory concentrations were obtained by linear regression from the dose-response lines obtained by plotting the prepared from homogenates of the livers of these hamsters. Alternatively, a live, hamster-adapted vaccine strain, Pneumabort (Fort Dodge Laboratories, Fort Dodge, Iowa) was used. Strain H45 (subtype 2) was also used in the in vitro studies.
The two field isolates of SHV-1 used were passaged in rabbit kidney (RK13) monolayers, and the supernatant tissue culture fluid was harvested when 80%o of the monolayer showed cytopathic effect. Virus suspensions were stored at -700C.
Hamsters were infected subcutaneously (s.c.) in the left flank with approximately 10 50o lethal doses of EHV-1, and mice were infected either s.c. in the left flank or intraperitoneally (i.p.) or by inhalation with approximately 2 50% lethal doses of SHV-1. In some experiments, surviving mice and hamsters were challenged with the respective viruses at the original virus concentration 14 days after primary infection.
Compounds and e ation. ACV as the sodium salt and compound BW759 were dissolved in sterile distilled water. Parenteral therapy was via the i. Immediately after blood sampling, the hamsters were killed, ¢he livers were removed aseptically, and small portions were fixed in buffered formol saline for histological examination. The remainder were weighed and then frozen to -700C pending bioassay. Conventional paraffin sections stained with hematoxylin and eosin wereexamined by light microscopy. For EHV-1 titrations, livers were thawed and homogenized 1/10 (wtlvol) in tissue culture maintenance medium with sterile Potter homogenizers, and a 10-ml portion of the homogenate was refrozen at -700C and thawed again.
Serial logl0 dilutions of this sample were then inoculated onto PK15 monolayers in 60-mm dishes, adsorbed for 1 h, and overlaid with a molten 1% agrose-doublestrength maintenance medium mixture. Dishes were incubated for 4 days in 5% C02-air at 37C and then fixed and stained before plaque counting. Results were expressed in PFU per gram of tissue.
In an attempt to follow the course of EHV 1-induced liver damage in the same hamster, the five hawsters in the fifth replicate cage per treatment group were serially blood sampled 3 days before infection and 22 and 65 h postinfection.
RESULTS
In vitro. Plaque reduction studies in PK15 monolayers gave 509o inhibitory concentrations of 2 and 0.06 ,uM for ACV and BW759 against EHV-1 (two strains) and 19 and 34 FM against SHV-1 (two strains), respectively.
Therapy of Aujeszky's dbeas virus infection in
mice. The mortality data for Aujeszky's disease are given in Table 1 . When the virus inoculum was administered s.c., total mortality always neared 100%o in mice treated i.p. and in untreated mice, but the time to death was increased by 12 to 24 h in both ACV-and BW759-treated mice. However, when the virus was inoculated via the i.p. or inhalation routes, not only was an increase in the incubation period of the disease noticeable in the BW759 group (50 mg/kg per day orally), but there was also a reduction in final mortality by about 20%o. ACV administered orally at 400 mg/kg per day appeared to have no effect in this case.
Therapy of EHV-1 infection in ha
Mortality. The results of the dose titration experiments are summarized in at 100 mg/kg per day (Fig. 2) . Uninfected hamsters treated with ACV at 100 mglkg per day showed a weight loss of 5% during treatment. In the infected hamsters treated with BW759 or ACV at 100 mg/kg per day, there were weight losses of 5.9 and 16.6%, respectively, compared with 8% in untreated, infected controls. At dose rates of 2 to 50 mg of BW759 per kg, hamsters showed positive weight gain. The variation within treatment was large, but the mean weight changes for ACV and BW759 (infected animals) come close to being significantly different, as do those for ACV and untreated (uninfected animals).
(0i) Virus multipliation in the liver. Table 3 shows the effect of ACV (v) Clinical chemistry parameters. There were significant changes in levels of certain liver enzymes and metabolites in plasma at various times postinfection (Table 4 ). In untreated control hamsters, levels of ALP were elevated at 41 h postinoculation; ALP, GPT, and BIL levels were all markedly elevated at 67 h; even higher levels were recorded at 89 h. In ACV-treated animals, levels were significantly lower than those in untreated controls at 67 and 89 h and were even lower in recipients of BW759. Comparison of the data obtained from hamsters which were serially sampled with those destructively sampled showed no significant differences for BIL at 22 and 67 h postinoculation or for GPT at 22 h, whereas there..were significant differences for GPT (0.05) and ALP (0.01) at 67 h. There were no significant time-related changes in concentrations of total protein (49 ± 6 g/liter), albumin (24 ± 2 g/liter), urea (6 ± 2 mmol/liter), gamma-glutamyl transpeptidase (3 with a similar medication regimen. They reported a 10-fold peak increase in serum GPT in infected, untreated controls compared with Ara-A-treated (35 mg/kg per day) hamsters. The analogous comparison for GPT in the present experiment gives values of 7-fold for ACV and 8.8-fold for BW759, suggesting a relatively greater effect of Ara-A in reducing liver damage; however, in the case of BW759, the dose rate used was equivilent to less than 1/10 of the Ara-A rate. Lieberman et al. (9) used Ara-A up to 250 mg/kg per day to obtain 80 to 90o survival, whereas 5-iodo-2'-deoxyurndine, distamycin A, and N-ethylisa-tin-thiosemicarbazone were ineffective in the dosage regimens used. Aswell et al. (2) obtained 60% survival with 1-D-arabinofuranosylthymine at 1,000 mg/kg per day, given i.p. every 4 h for 72 h, commencing 4 h preinfection; phosphonoacetic acid at 2,000 mg/kg per day, similarly administered, resulted in only 20% survival.
The superiority of BW759 over ACV might reflect different modes of action. ACV is only activated in virus-infected cells, where it is converted first to the monophosphate by a viruscoded thymidine kinase and thence to the di-and triphosphate by cellular phosphorylating enzymes. ACV triphosphate acts as a substrate for and competitively inhibits the viral DNA polymerase and effectively blocks viral DNA replication (10) . The high therapeutic index of ACV is a reflection of this specificity. On the basis of in vitro studies with drug-resistant strains, Smith et al. (11) and ACV, which has been found also with herpes simplex type 1 (Collins, personal communication), could be due in part to differing pharmacokinetic properties of the two compounds, but this has not been investigated in hamsters. The fact that all ACV-treated hamsters showed weight loss during medication, whereas a net live weight increase was recorded in recipients of BW759, is an additional advantage of the analog and indicates a higher therapeutic index.
None of the hamsters treated with BW759 or ACV and subsequently challenged with EHV-1 succumbed to infection, indicating that virus VOL. 24, 1983 on January 11, 2018 by guest http://aac.asm.org/ Downloaded from replication sufficient to elicit an immune response had occurred (assuming that the viral antigen in the initial inoculum alone was not immunogenic). That replication had occurred was demonstrated in the time course experiment. The results of the challenge experiment in mice surviving after SHV-1 infection were different, and it would seem that the initial inoculum used was not consistently immunogenic, since 50%o of the surviving untreated control and ACV-treated mice died after subsequent SHV-1 challenge. The slightly lower mortality in mice which had received BW759 (42 to 43%) might suggest that treatment had not completely inhibited viral multiplication but had restricted it to a level which was immunogenic rather than fatal.
The good correlation of the three criteria used to assess EHV-1 multiplication and consequent liver damage in experimentally infected hamsters was shown by the fact that clinical chemistry and histopathological observations reflected viral replication as determined by liver tissue bioassays. ALP appeared to be a more sensitive indicator of liver damage than BIL or GPT. Taking serial blood samples from individual hamsters to monitor concentrations of the plasma enzymes and metabolites diagnostic for liver damage is a useful means offollowing the development of virus-induced hepatitis and thereby of evaluating the efficacy of candidate antiviral agents. With this approach, quantitative results are obtained within a few hours rather than the days needed for histology and tissue culture bioassays; moreover, destructive sampling can be avoided, reducing the number of experimental animals required. However, the quantity needed per sample is relatively large in relation to the total blood volume, hence restricting the frequency of blood sampling from any one hamster.
It is considered that the results in this report demonstrate that BW759 is an extremely potent chemotherapeutic agent against EHV-1 and is marginally active against SHV-1. BW759 is clearly superior to ACV, although the reasons for this superiority remain to be elucidated. The excellent activity of BW759 after oral administration is particularly encouraging, as this would be an important route of administration in domestic animals.
